ArticleClinical and experimental dermatology2008
Inhibition of herpes simplex virus type 1 by small interfering RNA.
Article in Clinical and experimental dermatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Anti-HSV-1 agents: an update.Frontiers in pharmacology · 2024Review
- Article
- siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection.Virusdisease · 2019Article
- Cellular Protein Kinase D Modulators Play a Role during Multiple Steps of Herpes Simplex Virus 1 Egress.Journal of virology · 2018Article
- Quantitative Evaluation of Protein Heterogeneity within Herpes Simplex Virus 1 Particles.Journal of virology · 2017Article
- Argininosuccinate synthetase 1 depletion produces a metabolic state conducive to herpes simplex virus 1 infection.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Controllable inhibition of hepatitis B virus replication by a DR1-targeting short hairpin RNA (shRNA) expressed from a DOX-inducible lentiviral vector.Virus genes · 2013Article
- Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus.PLoS neglected tropical diseases · 2013Article
- Analysis of virion-incorporated host proteins required for herpes simplex virus type 1 infection through a RNA interference screen.PloS one · 2013Article
- Small interfering RNA targeting for infected-cell polypeptide 4 inhibits herpes simplex virus type 1 replication in retinal pigment epithelial cells.Clinical & experimental ophthalmology · 2012Article
- Article
- Inhibition of monkeypox virus replication by RNA interference.Virology journal · 2009Article
- Short hairpin-loop-structured oligodeoxynucleotides reduce HSV-1 replication.Virology journal · 2009Article
- RNA interference inhibits herpes simplex virus type 1 isolated from saliva samples and mucocutaneous lesions.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRNA interference, a conserved mechanism in which a sequence-specific gene-silencing process is mediated by small interfering RNA (siRNA), is a promising method of gene therapy in treating a variety of viral diseases.
aimTo investigate the antiviral effects of siRNA on herpes simplex virus type 1 (HSV-1) replication in Vero cells.
methodsThe antiviral effects of siRNA duplexes targeting the VP16 and DNA polymerase genes of HSV-1 were evaluated by yield-reduction and plaque-reduction assays. The effect of siRNA on the expression of target genes was measured by real-time quantitative reverse transcription PCR.
resultsTwo siRNA duplexes (siRNA-1, targeting VP16, and siRNA-4, targeting DNA polymerase), were found to be highly effective in inhibiting HSV-1 replication. siRNA-1 and siRNA-4 reduced HSV-1 replication by around 2 log(10) and 1 log(10) in the yield--reduction assay and by approximately 85% and approximately 70% in the plaque-reduction assay, respectively. Significant decreases in the mRNA level of VP16 and DNA polymerase genes were detected after viral infection in the Vero cells pretreated with siRNA-1 and siRNA-4, respectively.
conclusion:These results indicate that siRNA can potently inhibit HSV-1 replication in vitro, suggesting that siRNA-based antiviral therapy may be a potential effective therapeutic alternative for patients with HSV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.